Hannah’s Hope Fund provides funding to a collaborative team of scientists at various universities. Dr. Goldman’s group is working to understand the factors involved in regulating the function of gigaxonin in targeting intermediate filament proteins for degradation via the ubiquitin/proteasome pathway. We hope that working together with our group of scientists we will be able to identify new targets for disease intervention. Children with GAN do not have the time to wait for NIH funding cycles to translate findings. Dr. Goldman’s lab may help test candidate compounds identified by the collaborative team. HHF has the rights to these compounds. We are eternally grateful for Dr. Goldman’s very important work on this ravaging disorder.
|Effective start/end date||6/1/17 → 12/31/19|
- Hannah's Hope for Giant Axonal Neuropathy, Inc. (Check 1438)